Evidence that bisphenol A (BPA) can be accurately measured without contamination in human serum and urine, and that BPA causes numerous hazards from multiple routes of exposure

•  The basis for the FDA declaring BPA safe is shown to be false by findings reported in a large number of studies. 
•  The FDA claims that BPA is a ubiquitous environmental contaminant that is so pervasive that their BPA assay is contaminated. 
•  Numerous studies with uncontaminated assays show human blood BPA levels are high and associated with common human diseases. 
•  The FDA's assay contamination hypothesis is a manufactured controversy to reject findings relating BPA to human diseases. 
•  Statements in the abstracts of articles by authors concluding that BPA is safe are often discordant with their own data. 

There is extensive evidence that bisphenol A (BPA) is related to a wide range of adverse health effects based on both human and experimental animal studies. However, a number of regulatory agencies have ignored all hazard findings. Reports of high levels of unconjugated (bioactive) serum BPA in dozens of human biomonitoring studies have also been rejected based on the prediction that the findings are due to assay contamination and that virtually all ingested BPA is rapidly converted to inactive metabolites. NIH and industry-sponsored round robin studies have demonstrated that serum BPA can be accurately assayed without contamination, while the FDA lab has acknowledged uncontrolled assay contamination. In reviewing the published BPA biomonitoring data, we find that assay contamination is, in fact, well controlled in most labs, and cannot be used as the basis for discounting evidence that significant and virtually continuous exposure to BPA must be occurring from multiple sources.